ReviewCNS drug reviews2007
Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
Review in CNS drug reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.CNS drugs · 2023Pooled it
- Review
- Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Efficacy and safety of guanfacine in hospitalized patients with delirium: A scoping review.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Article
- Anxiety and school avoidance in an 8-year-old child with epilepsy.Epilepsy & behavior reports · 2024Article
- Article
- Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder.Psychopharmacology · 2020Article
- Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder.Soa--ch'ongsonyon chongsin uihak = Journal of child & adolescent psychiatry · 2020Article
- Article
- Article
- Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry.Autism research and treatment · 2012Article
- Guanfacine extended release in two patients with pervasive developmental disorders.Journal of child and adolescent psychopharmacology · 2011Article
- Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.Current psychiatry reports · 2010Review
- Cognitive enhancement as a pharmacotherapy target for stimulant addiction.Addiction (Abingdon, England) · 2010Review
- alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis.Neuroscience · 2009Article
- Norepinephrine and stimulant addiction.Addiction biology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Guanfacine, an alpha(2A) adrenoceptor agonist, is U.S. Food and Drug Administration (FDA)-approved for the treatment of hypertension in adolescents and adults. It also has been used "off-label" for several years in children as a possible treatment for attention-deficit/hyperactivity disorder (ADHD) and pervasive developmental disorders (PDDs). Small placebo-controlled trials support the use of guanfacine for the treatment of ADHD. There is more limited research on the use of guanfacine in treating hyperactivity occurring in children diagnosed with PDD. Recently, guanfacine extended release (GXR), a once-daily formulation has been manufactured and studied in phase III clinical trials. Based on preliminary scientific presentations, it also appears to be efficacious in improving ADHD in children. The most common adverse effects associated with guanfacine and GXR treatment is sedation. Adverse cardiovascular effects are uncommon, although modest reductions in blood pressure and heart rate are common. If GXR is FDA-approved, it would be the first alpha(2A) adrenoceptor agonist marketed for ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.